Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21598450 | 0.98 | SRC (0.47) | SRCPARP10PARP11TSHRSLC13A5 | |
| SCHEMBL652655 | 0.88 | PARP10 (0.43) | SRCPARP10PARP11PNMTPDE7A | |
| SCHEMBL10913809 | 0.76 | SRC (0.38) | SRCPARP10CA12CA1CA2 | |
| SCHEMBL1082367 | 0.76 | SRC (0.49) | SRCTSHRSLC13A5CA12CA1 | |
| SCHEMBL327043 | 0.76 | SRC (0.53) | SRCTSHRSLC13A5CA12CA1 | |
| SCHEMBL6359546 | 0.76 | SRC (0.53) | SRCPARP10PARP11TSHRSLC13A5 | |
| SCHEMBL5759503 | 0.76 | SRC (0.49) | SRCTSHRSLC13A5PNMTMEN1 | |
| SCHEMBL342322 | 0.76 | SRC (0.49) | SRCPARP10PARP11TSHRSLC13A5 | |
| SCHEMBL17969105 | 0.76 | SRC (0.49) | SRCTSHRSLC13A5CA12CA1 | |
| SCHEMBL13977383 | 0.76 | SRC (0.49) | SRCTSHRSLC13A5CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119702019-A | Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof | 湘潭大学 | 2025-03-28 | — | — | CN | claimed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| CN-119702019-A | Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof | 湘潭大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240270758-A1 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4332105-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-11882758-B2 | Heterocyclic compound, organic light-emitting device including heterocyclic compound, and electronic device including organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-23 | — | — | US | disclosed |
| CN-117222650-A | Pyridine or pyrimido-ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022228568-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-20210193927-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC DEVICE INCLUDING ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-06-24 | — | — | US | disclosed |
| WO-2004108678-A1 | (1,2,3,4-TETRAHYDROQUINOLIN-8-YL)-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-6734193-B1 | REDUCE SERUM GLUCOSE AND SERUM TRIGLYCERIDE LEVELS IN DIABETIC MAMMALS WITHOUT THE UNDESIRABLE PROPERTIES OF REDUCING SERUM THYROXINE LEVELS AND TRANSIENTLY RAISING TRIGLYCERIDE LEVELS | ALLERGAN, INC. | 2004-05-11 | — | — | US | disclosed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | disclosed |
| EP-0168035-B1 | USE OF ANILIN DERIVATIVES AS COUPLING AGENTS IN OXIDATIVE COLOUR-FORMING REACTIONS | Roche Diagnostics GmbH (DE) | 1991-10-09 | — | — | EP | disclosed |
| EP-0173208-A1 | Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0168035-A2 | Use of anilin derivatives as coupling agents in oxidative colour-forming reactions | Roche Diagnostics GmbH (DE) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | SRC 583/4885PARP10 1969/4885PARP11 805/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | SRC 353/4885PARP10 3305/4885PARP11 2329/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | SRC 583/4885PARP10 1969/4885PARP11 805/4885 |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | SRC 583/4885PARP10 1969/4885PARP11 805/4885 |
| US-20240270758-A1 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | KRAS, NRAS, BRAF | SRC 1478/4885PARP10 1691/4885PARP11 331/4885 |
| US-11882758-B2 | Heterocyclic compound, organic light-emitting device including heterocyclic compound, and electronic device including organic light-emitting device | LEF1, CYP1A1, CYP2E1 | SRC 4473/4885PARP10 3375/4885PARP11 1784/4885 |
| US-20210193927-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC DEVICE INCLUDING ORGANIC LIGHT-EMITTING DEVICE | LEF1, CYP1A1, CYP2E1 | SRC 4473/4885PARP10 3375/4885PARP11 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.